Part 1-Modelling of PK/PD for NPDDS.- Introduction to Nanoparticulate Drug Delivery Systems.- Nanoparticle Properties Affecting Pharmacokinetics of NPDDS.- Models Used for Biopharmaceutical Evaluation of NPDDS.- Models Used in the Pharmacokinetic Evaluation of NPDDS.- Models Used in the Pharmacodynamic Evaluation of NPDDS.- Preclinical Animal Models For Experimental Design of Pharmacokinetic Studies of NPDDS.- Pharmacokinetic Modelling Program (PKMP).- Part 2-PK/PD for Specific Nanocarriers.- Pharmacokinetic and Pharmacodynamics of Liposomal Nanoparticles.- Pharmacokinetics of Polymer Matrix Drugs (NPDDS).- Pharmacokinetics of Long-Circulating NPDDS.- Metallic Gold Nanoparticles in vivo Pharmacokinetics and X-ray Contrast imaging Studies.- Muco-adhesive NPDDS In Vitro and Pharmacokinetics Studies.- Pharmacokinetic and Tissue Distribution Study of Solid Lipid Nanoparticles.- Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles.- PKPD of PLGA-PEG-PLGA Triblock CoPolymeric Micelles.- Part 3-PKPD in Diseased Conditions for NPDDS.- Bridging Bio-Nanoscience and Cancer Nanomedicine.- Clearance Pathways and Tumor Targeting of Imaging Nanoparticles for Diagnostics.- PLGA Nanoparticles for Oral Delivery-Nephrotoxicity and Pharmacokinetic Studies.- Pharmacokinetics of Nanoparticle Systems for Pulmonary Delivery.- In vivo Biodistribution and Pharmacokinetic Studies of NPDDS for Brain Targeting.- Enhanced Bioavailability and Intestinal Uptake Nanoparticles After Oral Delivery.- Nanoparticle Pharmacokinetic Profiling In Vivo Using Magnetic Resonance Imaging.